Phase 1b/2 trial of ribociclib plus binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D).

被引：23

作者：

Schuler, Martin H.

Ascierto, Paolo A.

de Vos, Filip Yves Francine Leon

Postow, Michael Andrew

Van Herpen, Carla M. L.

Carlin, Matteo S.

Sosman, Jeffrey A.

Berking, Carola

Long, Georgina V.

Weise, Amy

Gutzmer, Ralf

Kaatz, Martin

McArthur, Grant A.

Schwartz, Gary

Daud, Adil

Maharry, Kati

Yerramilli-Rao, Padmaja

Zimmer, Lisa

Bozon, Viviana

Amaria, Rodabe Navroze

机构：

[1] Univ Hosp, West German Canc Ctr, Essen, Germany

[2] Ist Nazl Tumori Fdn G Pascale IRCCS, Naples, Italy

[3] Univ Med Ctr Utrecht, Canc Ctr, Dept Med Oncol, Utrecht, Netherlands

[4] Weill Cornell Med Coll, New York, NY USA

[5] Mem Sloan Kettering Canc Ctr, New York, NY USA

[6] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands

[7] Westmead & Blacktown Hosp, Sydney, NSW, Australia

[8] Melanoma Inst Australia, Sydney, NSW, Australia

[9] Northwestern Univ, Robert H Lurie Canc Ctr, Chicago, IL USA

[10] Univ Hosp Munich LMU, Dept Dermatol & Allergy, Munich, Germany

[11] Univ Sydney, Melanoma Inst Australia, Royal North Shore & Mater Hosp, Sydney, NSW, Australia

[12] Karmanos Canc Inst, Detroit, MI USA

[13] Hannover Med Sch, Skin Canc Ctr Hannover, Hannover, Germany

[14] SRH Wald Klinikum Gera GmbH, Gera, Germany

[15] Peter MacCallum Canc Ctr, Melbourne, Australia

[16] Columbia Coll Phys & Surg, New York, NY USA

[17] UCSF Helen Diller Family Comprehens Canc Ctr, Melanoma Clin Res, San Francisco, CA USA

[18] Array BioPharma Inc, Boulder, CO USA

[19] Novartis Inst BioMed Res, Cambrdige, MA USA

[20] Univ Texas MD Anderson Canc Ctr, Melanoma Med Oncol, Houston, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.9519

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9519

引用

页数：5

共 50 条

[21] CELEBRATE: A phase 1b study to evaluate the safety, tolerability and preliminary efficacy of the Combination of Encorafenib, Binimetinib and Palbociclib in patients with BRAF-mutant metastatic melanoma (The CELEBRATE study)
Soon, Jennifer A.
Weppler, Alison M.
Bailey, Chloe
Parente, Phillip
Kee, Damien
McArthur, Grant A.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 205 - 205
[22] Phase 1b/2 trial of tucatinib plus trastuzumab plus /-chemotherapy or pembrolizumab in patients with metastatic HER2+GI cancers
Shitara, Kohei
Park, Haeseong
Bekaii-Saab, Tanios
Kim, Sunnie S.
Kamath, Suneel
Pishvaian, Michael J.
Chen, Christopher
Zhen, David B.
Mayor, Joal
Tan, Qianwen
Strickler, John H.
ANNALS OF ONCOLOGY, 2022, 33 : S502 - S502
[23] Recommended phase 2 dose (RP2D) of HB-200 arenavirus-based cancer immunotherapies in patients with HPV16+cancers
Fu, Siqing
Nabell, Lisle
Pearson, Alexander T.
Leidner, Rom
Adkins, Douglas
Posner, Marshall R.
Nieva, Jorge J.
Richardson, Debra L.
Pimentel, Agustin
Goel, Sanjay
Wong, Stuart J.
Ho, Alan Loh
Rosenberg, Ari
Taylor, Matthew H.
Abdul-Karim, Raghad
Iacobucci, Corinne
Qing, Xiaoping
Katchar, Kia
Schlienger, Katia
Pfister, David G.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[24] Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
Spring, Laura M.
Clark, Shealagh L.
Li, Tianyu
Goel, Shom
Tayob, Nabihah
Viscosi, Elene
Abraham, Elizabeth
Juric, Dejan
Isakoff, Steven J.
Mayer, Erica
Moy, Beverly
Supko, Jeffrey G.
Tolaney, Sara M.
Bardia, Aditya
NPJ BREAST CANCER, 2021, 7 (01)
[25] Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
Laura M. Spring
Shealagh L. Clark
Tianyu Li
Shom Goel
Nabihah Tayob
Elene Viscosi
Elizabeth Abraham
Dejan Juric
Steven J. Isakoff
Erica Mayer
Beverly Moy
Jeffrey G. Supko
Sara M. Tolaney
Aditya Bardia
npj Breast Cancer, 7
[26] A Phase 2 Trial of Bevacizumab and High-dose Interferon Alpha 2B in Metastatic Melanoma
Grignol, Valerie P.
Olencki, Thomas
Relekar, Kiran
Taylor, Cynthia
Kibler, Amanda
Kefauver, Cheryl
Wei, Lai
Walker, Michael J.
Chen, Helen X.
Kendra, Kari
Carson, William E., III
JOURNAL OF IMMUNOTHERAPY, 2011, 34 (06) : 509 - 515
[27] NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with untreated or progressed after first-line immunotherapy unresectable or metastatic NRAS-mutant cutaneous melanoma
Flaherty, Keith
Arenberger, Petr
Ascierto, Paolo Antonio
De Groot, Jan Willem
Hallmeyer, Sigrun
Long, Georgina V.
Lotem, Michel
Marples, Maria
Schadendorl, Dirk
Starodub, Alexander
Taylor, Matthew Hiram
Wolter, Pascal
Yamazaki, Naoya
Wasserman, Ernesto
Ford, James
Weill, Marine
Dummer, Reinhard
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[28] Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study
Gupta, Vikas
Wolleschak, Denise
Hasselbalch, Hans
Vannucchi, Alessandro Maria
Koschmieder, Steffen
Cervantes, Francisco
Li, Yang
Dong, Tuochuan
Wroclawska, Monika
Bharathy, Savita
Harrison, Claire
BLOOD ADVANCES, 2020, 4 (13) : 3063 - 3071
[29] Recommended phase 2 dose (RP2D) for abemaciclib in combination with irinotecan (IRN) and temozolomide (TMZ) in pediatric patients with relapsed/refractory solid tumors (JPCS Part A)
Lassaletta, Alvaro
Moreno, Lucas
Ogawa, Chitose
Ruggiero, Antonio
Hoffman, Lindsey M.
Pitou, Celine
Zhou, Yanhong
Hardebeck, Molly C.
Knoderer, Holly
Juan-Ribelles, Antonio
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[30] Results of COLUMBUS Part 2: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus ENCO in BRAF - Mutant Melanoma
Dummer, Reinhard
Ascierto, Paolo A.
Gogas, Helen J.
Arance, Ana
Mandala, Mario
Liszkay, Gabriella
Garbe, Claus
Schadendorf, Dirk
Krajsovÿ, Ivana
Gutzmer, Ralf
Sileni, Vanna Chiarion
Dutriaux, Caroline
de Groot, Jan Willem B.
Yamazaki, Naoya
Loquai, Carmen
de Parseval, Laure A.
Pickard, Michael
Sandor, Victor
Berking, Carola
Robert, Caroline
Flaherty, Keith T.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 12 - 13

← 1 2 3 4 5 →